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Introduction: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a 
novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 
immunoreactivity in colorectal carcinogenesis and its correlation with prognosis.
Methods: DCLK1 immunostaining was performed in colorectal tissue from 71 patients, includ-
ing 18 adenomatous polyps, 40 primary adenocarcinomas, and 14 metastatic lesions. Each case 
was evaluated by a combined scoring method based on the intensity of staining (score 0–3) 
and the percentage of tissue staining positive (score 0–3). Immunoexpression for DCLK1 was 
considered as positive when the combined score was 2–6 and negative with a score of 0–1.
Results: Overall, 14/18 (78%) of polyps, 30/40 (75%) of primary adenocarcinomas, and 7/14 
(50%) of distant metastases were positive for DCLK1. In adenomatous polyps and primary cancer 
there was no association between DCLK1 staining score and tumor pathology. However, after 
curative colorectal cancer resection, patients whose tumor had a high ($5) combined staining 
score had increased cancer-specific mortality compared to patients with low (0–4) staining score 
(hazard ratio 5.89; 95% confidence interval: 1.22–28.47; P = 0.027).
Conclusion: We found that DCLK1 is frequently expressed in colorectal neoplasia and may 
be associated with poor prognosis. Further studies are necessary to validate the use of DCLK1 
as a prognostic marker.
Keywords: DCLK1, DCAMKL-1, gastrointestinal stem cell, cancer stem cell, adenomatous 
polyps, liver metastasis, immunohistochemistry
Introduction
Colonic carcinogenesis is known to occur through the accumulation of genetic 
mutations over a long time frame.1 Recently, lineage-tracing studies have shown 
that Apc deletion in long-lived stem cells expressing leucine-rich-repeat-containing 
G-protein-coupled receptor 5 (LGR5) gives rise to intestinal adenoma in mice, which 
lends support to the intestinal stem cell as the possible cell of origin for colorectal 
cancer.2 Several candidate markers of the intestinal stem cell population, such as 
LGR5, MSI1, and CD29, have been extensively studied.3 Recently, doublecortin and 
CaM kinase-like-1 (DCLK1, previously referred to as DCAMKL-1), a transmem-
brane microtubule-associated kinase found in post-mitotic neurons,4 has also been 
proposed as intestinal stem cell marker. In support of this, 1 DCLK1 was found to be 
abundant in mouse cDNA libraries from gastrointestinal progenitor cells.5 Moreover, 
DCLK1-positive cells were shown to retain bromodeoxyuridine and to form glandular 
epithelial structures when injected in nude mice.6 Although DCLK1 has been shown to 
be expressed in cancers, including pancreatic and esophageal,7–9 the data on DCLK1 
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immunoreactivity in human colorectal cancer are limited.7 
Moreover, the expression of DCLK1 during progressive 
tumorigenesis has not been studied. The aim of this study was 
to further elucidate the expression of DCLK1 in colorectal 
carcinogenesis by evaluating DCLK1 immunoreactivity in 
colorectal adenomatous polyps, adenocarcinomas, and distant 
metastases. In addition, we sought to elucidate whether the 
expression of DCLK1 correlated with the degree of carcino-
genesis and with prognosis.
Materials and methods
Patients
Pathology reports and the corresponding hematoxylin and 
eosin slides of patients treated at Tulane University Health 
Science Center between January 2000 and December 2010 
were retrospectively reviewed. Patients with adenomatous 
polyps, primary colorectal adenocarcinomas, and colorectal 
metastases were identified. Representative tissue blocks 
were selected from 18 patients with benign colorectal 
polyps who underwent polypectomy and from 40 patients 
with primary colorectal adenocarcinomas who underwent 
surgical resection. We only included those colorectal cancer 
patients who had surgery before 2008 and excluded those 
who underwent neoadjuvant therapy. Colorectal distant 
metastases (13 liver and one lung) were selected among 
patients who underwent surgery for metastatic cancer. 
Demographics, tumor location, size, degree of dysplasia, 
American Joint Committee on Cancer (AJCC) stage, and 
degree of differentiation were extracted from the pathol-
ogy reports. Lesions with the morphologic characteristics 
of adenocarcinomas but that had not invaded through the 
muscularis mucosae into the submucosa were classified 
as “intramucosal neoplasia”. For patients with primary 
colorectal cancer, updated follow-up information including 
disease status and cause of death was obtained from Tulane 
Cancer Center. The study was approved by the Tulane 
University Institutional Review Board.
Immunohistochemistry
Immunohistochemical staining was carried out on 5-mm 
sections of formalin-fixed, paraffin-embedded samples. For 
all experiments we used a rabbit polyclonal anti-DCLK1 
antibody (1:80; Abcam, Cambridge, MA). Heat-induced 
epitope retrieval was performed utilizing a pressurized 
food steamer in citrate buffer (pH 6.0) at 99°C. Primary 
antibody incubation was carried out overnight at 4°C. For all 
experiments we used the UltraVision LP Detection System 
kit (Thermo Fisher Scientific, Fremont, CA) following the 
instructions of the manufacturer. To exclude nonspecific 
staining, isotype (rabbit polyclonal IgG; Abcam) and nega-
tive controls were included for each experiment. A colorec-
tal cancer with intense immunoreactivity for DCLK1 was 
used as positive control. Immunostaining was performed 
in duplicate.
Staining evaluation
DCLK1 staining intensity in tumor cells was evaluated in a 
blinded fashion by one pathologist (MG) to assign scores of 
average immunohistochemical signal intensity (ie, 0 = none, 
1 = mild, 2 = moderate, and 3 = strong) as well as the percent-
age of tissue showing positive immunoreactivity (Table 1). 
Signal intensity and percentage of positive tissue were 
combined in a staining score similar to that described for the 
intestinal stem cell marker LGR5.10–12 Immunoexpression for 
DCLK1 was considered positive when the combined score 
was 2–6 and negative with a score of 0–1.
Statistical analysis
The association between staining score, patient characteris-
tics, and tumor features was tested using the Fisher’s exact 
test for qualitative variables and the Mann–Whitney test 
for quantitative ones. For the primary colorectal cancers, 
the cutoff point between staining scores with different 
prognostic values was calculated using a receiver-operating 
characteristic curve based on cancer-specific mortality 
(CSM). CSM curves were estimated by the Kaplan–Meier 
method and compared using the log-rank test; CSM was then 
analyzed by the Cox proportional hazards model, comparing 
the risk factors by the Wald test. No multivariate model was 
estimated, due to the low number of events. All reported 
P-values were obtained by the two-sided exact method, and 
significance was established at the conventional 5% level. 
Data were analyzed using SPSS software (version 19.0; 
SPSS, Chicago, IL).
Table 1 Scoring criteria
Features Score
Intensity of staining
  Nonreactive 0
  Mild 1
  Moderate 2
  Strong 3
Percentage of positive cells
 , 5% 0
  5%–30% 1
  31%–60% 2
  61%–100% 3
Note: Total score: 0–1 = negative; 2–6 = positive.
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Results
Adenomatous polyps
We identified 18 cases of adenomatous polyps. The mean 
age was 58 years (range 40–84 years). Nine of the polyps 
were located in the right colon, four in the left colon, and 
five in the rectum. Polyp architecture was tubular in three 
cases, tubulovillous in 13 cases, and villous in two cases 
(Table 2). The correlation of DCLK1 expression with vari-
ous clinicopathologic features is detailed in Table 2. Of the 
18 adenomas, 14 (78%) showed positive immunoreactivity 
for DCLK1 (Table 2). Staining was granular and localized 
to the apical (luminal) part of the cytoplasm (Figure 1). 
Staining was present focally or expressed over large areas 
of the adenoma. No significant associations were found 
between staining score and polyp location, size, morphol-
ogy, architecture, degree of dysplasia, or the presence of 
carcinomas in situ. However, a staining score of $5 was 
found in 38% (5/13) of the adenomas with high-grade 
dysplasia compared to 0% (0/5) of the adenomas with 
low-grade dysplasia.
Adenocarcinomas
We identified 40 cases of colorectal adeoncarcinomas in the 
database of our institution for which paraffin blocks were 
available. The mean age of the patients was 66 years (range 
30–98 years). Eighteen tumors were located in the right colon, 
16 in the left colon, and six in the rectum. There were six 
AJCC stage I, eight stage II, 20 stage III, and six stage IV 
tumors (Table 3). The correlation of DCLK1 expression 
with various clinicopathologic features is detailed in Table 3. 
Immunostaining was positive in 30/40 (75%) of the adeno-
carcinomas (Table 3) with a staining pattern similar to that 
observed in the polyps, either focal (Figure 2A) or diffuse 
(Figure 2B). Focal immunoreactivity was also found in the 
tumor desmoplastic stroma. Histologically normal mucosa 
adjacent to tumors was evaluated in 37 cases of which 28 
(76%) showed positive DCLK1 immunoreactivity (Figure 3). 
In three-paired nodal metastases the pattern of staining 
Table 2 Clinicopathologic and DCLK1 immunostaining characteristics in 18 adenomatous polyps
Age at  
diagnosis  
(years)
Gender Polyp  
location
Morphology Architecture Size  
(mm)
Grade of  
dysplasia
Intramucosal  
neoplasia
Intensity  
of staining
Area of  
staining (%)
Combined 
score
51 M Right Sessile Tubulovillous 20 high No 2 10% 3
57 M Left Sessile Tubulovillous 18 high No 3 100% 6
56 M Right Sessile Tubulovillous 20 Low No 0 0% 0
55 M Rectum Pedunculated Villous 20 Low No 2 60% 4
40 M Left Pedunculated Tubular 18 high Yes 2 100% 5
56 M Left Pedunculated Tubulovillous 35 high No 3 60% 5
84 M Right Pedunculated Tubulovillous N/A Low No 2 50% 4
42 M Rectum Sessile Tubulovillous N/A high Yes 0 0% 0
57 M Right Sessile Tubulovillous N/A Low No 2 40% 4
68 M Right Sessile Tubulovillous 20 high No 2 50% 4
65 F Left Pedunculated Tubulovillous 15 Low No 2 10% 3
66 M Rectum Sessile Villous 50 high Yes 2 50% 4
66 M Rectum Sessile Tubular 8 high No 2 10% 3
59 F Right Sessile Tubular 50 high Yes 0 0% 0
64 M Right Sessile Tubulovillous 50 high Yes 1 25% 2
50 M Right Sessile Tubulovillous 15 high Yes 2 80% 5
64 M Rectum Sessile Tubulovillous 25 high Yes 3 70% 5
50 F Right Pedunculated Tubulovillous 50 high Yes 0 0% 0
Abbreviations: DCLK1, doublecortin and CaM kinase-like-1; N/A, not available; M, male; F, female.
Figure 1 Moderate DCLK1 immunoreactivity in a tubulovillous adenoma with low-
grade dysplasia (100×). Granular staining localized to the apical part of the cytoplasm 
(arrows).
Abbreviation: DCLK1, doublecortin and CaM kinase-like-1.
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Figure 2 (A) Focal DCLK1 immunoreactivity in a moderately differentiated adenocarcinoma (200×). (B) Diffuse DCLK1 immunoreactivity in a moderately differentiated 
adenocarcinoma (100×).
Abbreviation: DCLK1, doublecortin and CaM kinase-like-1.
Figure 3 DCLK1 immunoreactivity in the normal colonic mucosa (dashed arrow) 
adjacent to the tumor (solid arrow) (100×).
Abbreviation: DCLK1, doublecortin and CaM kinase-like-1.
in metastatic tissue mirrored that of the primary tumor. 
An example of DCLK1 immunoreactivity in a metastatic 
lymph node is shown in Figure 4. No significant associations 
were found between staining score and tumor location, AJCC 
stage, or degree of differentiation.
Distant metastasis
Of the 14 distant (13 liver and one lung) colorectal metastases, 
seven (50%) had immunoreactivity for DCLK1. Similar to 
that observed in the primary tumors, the staining was predomi-
nately cytoplasmic. In addition, three tumors showed areas 
with strong apical membrane localization. An example of a 
liver metastasis with both cytoplasmic and membrane staining 
is shown in Figure 5. Focal immunoreactivity was found in 
the desmoplastic stroma. For one liver metastasis, the primary 
tumor was available. Interestingly, there was DCLK1 immu-
noreactivity in both the primary and metastatic tissue.
Survival analysis in primary colorectal 
cancer
At a median follow-up of 52 months (range 2–110) of 40 
patients with primary colorectal cancer, 19 were alive without 
evidence of recurrence, 16 died of colorectal cancer, three 
died of other causes (including two perioperative deaths) and 
two were lost to follow-up (Table 3). Using cancer-specific 
mortality as the endpoint, receiver-operating characteristic 
curve calculations showed the most accurate cutoff point 
for the staining score was $5, with an accuracy of 68.9%, a 
sensitivity of 64.3%, and a specificity of 69.2%. Using two 
different staining score cutoff points (either $2 or $5), 
patients and tumor characteristics were tested in univariate 
binary logistic regression models as independent predictors 
of staining score. No associations were found between score 
and AJCC stage or degree of differentiation using either the 
cutoff point of $2 or $5.
Figure 4 DCLK1 immunoreactivity in a metastatic lymph node (200×).
Abbreviation: DCLK1, doublecortin and CaM kinase-like-1.
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CSM was severely increased in patients with a high ($5) 
staining score compared to patients with low (0–4) stain-
ing score (hazard ratio 4.16; 95% confidence interval [CI]: 
1.28–13.57; P = 0.018). The Kaplan–Meier cancer-specific 
survival curve for patients with high ($5) and low (0–4) 
staining score is shown in Figure 6. This strong risk factor 
persisted even after eliminating patients diagnosed at stage IV 
(hazard ratio 5.89; 95% CI: 1.22–28.47; P = 0.027).
Discussion
The relationship of DCLK1-expressing cells to crucial events 
in tumor progression is poorly understood. Using standard 
immunostaining, we noted DCLK1 immunoreactivity in 78% 
of colorectal adenomas, and in 75% of primary colorectal 
cancers. This finding suggests that the upregulation of 
DCLK1 might be an early event in colorectal tumorigenesis. 
We also noted that nearly 40% of adenomatous polyps 
with high-grade dysplasia expressed intense DCLK1 
immunoreactivity. This finding is similar to the results of 
other   investigators who found an increased expression of 
the putative intestinal stem cell marker LGR5 in high-grade 
precancerous colorectal lesions.12 These findings are also 
consistent with the animal data showing that Apc gene dele-
tion in LGR5-positive cells gives rise to intestinal adenomas,2 
and provide indirect evidence of the involvement of adult 
intestinal stem cells in colorectal carcinogenesis. However, 
the role of DCLK1 as an intestinal stem cell marker is still 
a matter of debate, since recent studies in a mouse model 
suggest that DCLK1-expressing cells represent postmitotic 
differentiated tuft cells and enteroendocrine cells.13
While these results confirm the increased immunohis-
tochemical expression of DCLK1 in primary colorectal 
cancer, we also noted DCLK1 immunoreactivity in the 
histologically normal mucosa immediately adjacent to the 
adenocarcinomas in 76% of cases. This is in contrast to 
the findings of Sureban and colleagues, who did not identify 
any immunoreactivity in paired normal mucosa from tissue 
microarrays.7,14 However, studies of tissue microarrays do not 
examine the tumor–mucosal junction, which in colorectal can-
cer, is known to be hyperplastic and to contain more immature 
and undifferentiated cells.15–19 These findings may therefore 
reflect a process of clonal activation starting in intestinal stem 
cells and the phenomenon of field cancerization.20
The presence of DCLK1-expressing cells in colorectal 
metastases has not been described. In our study, we found 
high DCLK1 expression not only in the primary tumors but 
also in the distant metastases, which is consistent with the 
results of other investigators who found a similar expression 
of the putative intestinal stem cell marker LGR5 in primary 
colorectal carcinomas and liver metastases.21 In distant metas-
tases, we noted that DCLK1 immunoreactivity was positive 
in 50% of our specimens, with a staining pattern similar to 
that observed in the primary tumors. These results raise the 
question of whether DCLK1 in metastases might have their 
origin in primary tumors. We believe that DCLK1-expressing 
tumor cells become detached from the primary tumor site and 
migrate to the metastatic site via vascular and/or perineural 
spaces. However, our results are difficult to interpret, because 
paired tissue from the primary tumors was available in only 
a minority of samples.
While there was no association of DCLK1 expression with 
the stage of disease or the degree of tumor differentiation, we 
found that a high level of DCLK1 immunoreactivity correlated 
with a worse cancer specific survival and, therefore, may 
reflect a more aggressive tumor phenotype. The reason why 
Figure 5 DCLK1 immunoreactivity in a liver metastasis showing both cytoplasmic 
(dashed arrow) and apical membrane (solid arrow) localization (400×).
Abbreviation: DCLK1, doublecortin and CaM kinase-like-1.
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Figure 6 Kaplan–Meier cancer-specific survival curve for patients with high ($5) 
and low (0–4) DCLK1 staining score.
Note: *Log-rank test.
Abbreviation: DCLK1, doublecortin and CaM kinase-like-1.
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colorectal cancers expressing high levels of DCLK1 behave 
more aggressively may be related to the cancer stem cell 
theory. This theory postulates that only a subset of cancer cells 
with stem-like features are capable of reproducing the tumor 
and metastasizing and that, in colorectal cancer, these cells 
express intestinal stem cell markers.3,22 Although an associa-
tion between tumor expression and a worse colorectal cancer 
prognosis has been observed with other candidate intestinal 
stem cell markers including LGR5 and Musashi-1,23,24 the 
small number of subjects in our cohort limits the power of 
the study and gives rise to wide confidence intervals. Another 
limit of our study is that the follow-up was not standardized. 
Therefore our results must be viewed with caution and must be 
confirmed in a larger patient population. Moreover, our results 
are only based on immunohistochemical analysis which does 
not quantify protein expression. Future studies should include 
quantitative evaluation of DCLK1 by reverse transcriptase 
polymerase chain reaction or fluorescence-activated cell sort-
ing in both normal and neoplastic colorectal tissue.
Although several putative colorectal cancer stem cells 
markers have been identified, it is not clear how these mark-
ers can be used clinically. Interestingly, Sureban and col-
leagues showed that after small-interfering RNA blockage of 
DCLK1, colon cancer cells had reduced in vivo tumorigenic 
potential. This functional role was mediated by a decrease of 
the MIRLET7 A primary transcript and an increase of Myc 
expression, both related to loss of epithelial differentiation.7 
In a recent study, administration of a nanoparticle-based 
DCLK1 small interfering RNA into a colorectal tumor 
xenograft inhibited tumor growth and downregulated Myc 
and Notch1.14 These studies suggest that DCLK1 may be a 
marker of colorectal stem cells with a functional role and 
thus may be an important therapeutic target.
In conclusion, these results demonstrate that DCLK1 is 
commonly expressed in colorectal adenomas and carcinomas 
and that a high DCLK1 staining score may have prognostic 
value. Our results suggest an active involvement of DCLK1 in 
colorectal carcinogenesis. However, further studies are neces-
sary to validate the use of DCLK1 as a colorectal cancer stem 
cell marker and as a possible therapeutic target.
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